文献速递眼底病与葡萄膜炎

AAV基因增强疗法在RDH5-/-猫模型中挽救眼底白点症表型

AAV Gene Augmentation Therapy Rescues the Phenotype in the RDH5-/- Cat Model of Fundus Albipunctatus.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究在RDH5基因敲除猫(眼底白点症模型)中,通过视网膜下注射携带猫RDH5 cDNA的AAV2三衣壳突变载体(AAV-VMD2-fRDH5),评估基因增强疗法的效果。结果显示,RDH5转基因表达可改善视杆和视锥细胞在光照后的功能恢复,并显示出减缓或阻止中央区(类似人黄斑)退变的潜力。结论认为该疗法是治疗RDH5相关视网膜病变的有前景方法。

要点

  • AAV-VMD2-fRDH5视网膜下注射可恢复RDH5-/-猫的视杆和视锥细胞功能。
  • 治疗显示出减缓或阻止中央区(类似人黄斑)退变的潜力。
  • 该基因增强疗法是RDH5相关视网膜病变的有前景治疗策略。

核心结论

  • AAV介导的RDH5基因增强疗法在RDH5-/-猫模型中改善了视杆和视锥细胞功能,并可能减缓中央区退变。
  • 该疗法是治疗RDH5相关视网膜病变的有前景方法。

研究设计与样本

  • 研究使用12只RDH5-/-猫,视网膜下注射AAV2三衣壳突变载体包装的猫RDH5 cDNA(AAV-VMD2-fRDH5)。
  • 采用免疫组化、高效液相色谱、视杆和视锥视网膜电图、谱域光学相干断层扫描及半薄树脂包埋切片评估表达与疗效。

主要发现

  • RDH5转基因表达改善了光照后视杆和视锥 photoreceptor 的功能恢复。
  • 治疗显示出减缓或阻止中央区(类比人黄斑)退变的潜力。

临床怎么用

  • 对于RDH5突变导致的眼底白点症,基因增强疗法可能成为未来治疗选择,但需进一步临床验证。

局限性

  • 研究仅使用猫模型,样本量有限(12只),尚未在人体中验证。
  • 原文未报告长期疗效和安全性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Retinol dehydrogenase 5 (RDH5) catalyzes the final oxidation for visual pigment regeneration of 11-cis-retinal as part of the visual cycle in the retinal pigment epithelium (RPE). In humans, RDH5 mutations cause fundus albipunctatus characterized by night blindness, accumulation of white-yellowish fundus spots, and, in a subset of patients, macular degeneration. Currently, there is an unmet need for therapies for patients with RDH5 mutations. Using a large-animal cat model of RDH5-associated disease (RDH5-/-), this study aimed to meet these needs through development of a gene augmentation therapy able to rescue RDH5-associated retinopathies. METHODS: An adeno-associated virus serotype 2 with triple capsid mutations vector packaged with feline RDH5 cDNA (AAV-VMD2-fRDH5) was subretinally injected into 12 RDH5-/- cats. To assess expression and the impact of treatment on retinal function and structure, immunohistochemistry, high-performance liquid chromatography, rod and cone electroretinograms, spectral-domain optical coherence tomography, and semi-thin resin-embedded sectioning were performed. RESULTS: The expression of the RDH5 transgene improved rod and cone photoreceptor functional recovery following light exposure and shows promise in slowing/halting area centralis (analogous to the human macula) degeneration. CONCLUSIONS: This gene augmentation therapy is a promising approach for the treatment of RDH5-associated retinopathies.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Ford LM, Sun K, Occelli LM, et al. AAV Gene Augmentation Therapy Rescues the Phenotype in the RDH5-/- Cat Model of Fundus Albipunctatus. Invest Ophthalmol Vis Sci. 2026. PMID: 42904881. doi:10.1167/iovs.67.12.45

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。